Management of Refractory Orbital Inflammation

Medication Regimen

The current prednisone dose should be maintained at the minimum effective dose to prevent disease flares, with a very slow taper for steroid-dependent patients, reducing by only 1mg every 2-4 weeks once below 10mg daily, as recommended by the Mayo Clinic 1
Methotrexate is an appropriate steroid-sparing agent, with a recommended dose of 15-25mg weekly, and folic acid supplementation at 2mg daily to minimize methotrexate side effects 1
A gradual steroid taper, reducing by only 1mg every 4 weeks when attempting to go below the current dose, is recommended by the Mayo Clinic 1

Subcutaneous administration of methotrexate may improve efficacy and reduce side effects, with better bioavailability and potentially better disease control at the current dose, as recommended by the American College of Rheumatology 2
Ensuring adequate folic acid supplementation is necessary to minimize methotrexate side effects 2

Regular ophthalmologic examinations and routine laboratory monitoring, including complete blood count, liver function tests, and bone density scans, are necessary to assess disease activity and treatment response 1, 2
Adequate calcium and vitamin D supplementation, and consideration of bone-protective agents such as bisphosphonates, are necessary to prevent further steroid-induced fractures 1, 2

A multi-drug approach, including rituximab, methotrexate, and prednisone, is recommended for refractory orbital inflammation, with careful monitoring and optimization of the treatment regimen, as suggested by the American College of Rheumatology 1, 2
Maintenance therapy with rituximab is appropriate for patients with recalcitrant disease, with maintenance dosing and potential retreatment when breakthrough inflammation occurs 2
Alternate-day dosing of prednisone may be considered to reduce side effects while maintaining efficacy 2